NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 166)
Posted On: 10/18/2019 6:18:20 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Utilizing Artificial Intelligence, Smart Tumor Profiling to Augment Clinical Outcomes
Predictive Oncology (NASDAQ: POAI), a developer of highly adaptable assessment methods for cancer patients to help guide personalized treatments, employs its proprietary smart tumor profiling and artificial intelligence (“AI”) platform to predict tumor drug response and improve clinical outcomes for cancer patients. An article discussing the company’s activities further reads, “Last year, POAI, then known as Precision Therapeutics, formed TumorGenesis to focus on innovative ways to create improved patient-derived (PDx) tumor models. Currently, TumorGenesis is working on developing new techniques for growing tumors in the lab to generate more relevant models of the tumors that can be used to test drugs for personalized therapy or aid in development of new medications. . . .The approach is designed to grow tumors in the lab by providing an environment that closely mimics the human body through the use of chemistry, biology, mechanics and cell nutrients. In addition to this exclusive technology being quicker and more affordable than existing PDx animal models, researchers anticipate that the approach will better replicate the characteristics of tumors. Initially, the company plans to develop PDx models for multiple myeloma, triple-negative breast cancer and ovarian cancer, but Predictive is expecting the technology to ultimately benefit oncologists who are investigating other cancer areas as well, including liver, pancreatic, lung and colon.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a developer of highly adaptable assessment methods for cancer patients to help guide personalized treatments, employs its proprietary smart tumor profiling and artificial intelligence (“AI”) platform to predict tumor drug response and improve clinical outcomes for cancer patients. An article discussing the company’s activities further reads, “Last year, POAI, then known as Precision Therapeutics, formed TumorGenesis to focus on innovative ways to create improved patient-derived (PDx) tumor models. Currently, TumorGenesis is working on developing new techniques for growing tumors in the lab to generate more relevant models of the tumors that can be used to test drugs for personalized therapy or aid in development of new medications. . . .The approach is designed to grow tumors in the lab by providing an environment that closely mimics the human body through the use of chemistry, biology, mechanics and cell nutrients. In addition to this exclusive technology being quicker and more affordable than existing PDx animal models, researchers anticipate that the approach will better replicate the characteristics of tumors. Initially, the company plans to develop PDx models for multiple myeloma, triple-negative breast cancer and ovarian cancer, but Predictive is expecting the technology to ultimately benefit oncologists who are investigating other cancer areas as well, including liver, pancreatic, lung and colon.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)